Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:18
|
作者
Kontorinis, Georgios [1 ,2 ]
Nichani, Jaya [1 ]
Freeman, Simon R. [1 ]
Rutherford, Scott A. [3 ]
Mills, Samantha [4 ]
King, Andrew T. [3 ]
Mawman, Deborah [1 ]
Huson, Sue [5 ]
O'Driscoll, Martin [1 ]
Gareth Evans, D. [5 ]
Lloyd, Simon K. W. [1 ,6 ,7 ]
机构
[1] Cent Manchester Univ Hosp, NHS Fdn Trust, Univ Dept Otolaryngol, Manchester M13 9PL, Lancs, England
[2] Southern Teaching Hosp, Inst Neurosci, Dept Otolaryngol, Glasgow, Lanark, Scotland
[3] Salford Royal NHS Fdn Trust, Dept Neurosurg, Manchester, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Neuroradiol, Manchester, Lancs, England
[5] Cent Manchester Univ Hosp, NHS Fdn Trust, Dept Med Genet, Manchester M13 9PL, Lancs, England
[6] Univ Manchester, Sch Canc, Manchester M13 9PL, Lancs, England
[7] Univ Manchester, Enabling Serv, Manchester M13 9PL, Lancs, England
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol; VESTIBULAR SCHWANNOMAS; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; COCHLEAR IMPLANTATION; UNITED-KINGDOM; GROWTH; PRESERVATION; NF2;
D O I
10.1007/s00405-014-3317-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:8
相关论文
共 50 条
  • [1] Progress of hearing loss in neurofibromatosis type 2: implications for future management
    Georgios Kontorinis
    Jaya Nichani
    Simon R. Freeman
    Scott A. Rutherford
    Samantha Mills
    Andrew T. King
    Deborah Mawman
    Sue Huson
    Martin O’Driscoll
    D. Gareth Evans
    Simon K. W. Lloyd
    European Archives of Oto-Rhino-Laryngology, 2015, 272 : 3143 - 3150
  • [2] MECHANISMS OF HEARING LOSS IN NEUROFIBROMATOSIS TYPE 2
    Asthagiri, Ashok
    Vasquez, Raul
    Butman, John
    Wu, Tianxia
    Morgan, Keaton
    Brewer, Carmen
    King, Kelly
    Zalewski, Chris
    Kim, H. Jeffrey
    Lonser, Russell
    NEURO-ONCOLOGY, 2012, 14 : 124 - 124
  • [3] Mechanisms of Hearing Loss in Neurofibromatosis Type 2
    Asthagiri, Ashok R.
    Vasquez, Raul A.
    Butman, John A.
    Wu, Tianxia
    Morgan, Keaton
    Brewer, Carmen C.
    King, Kelly
    Zalewski, Chris
    Kim, H. Jeffrey
    Lonser, Russell R.
    PLOS ONE, 2012, 7 (09):
  • [4] Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2
    Dinh, Christine T.
    Nisenbaum, Eric
    Chyou, Darius
    Misztal, Carly
    Yan, Denise
    Mittal, Rahul
    Young, Juan
    Tekin, Mustafa
    Telischi, Fred
    Fernandez-Valle, Cristina
    Liu, Xue-Zhong
    OTOLOGY & NEUROTOLOGY, 2020, 41 (05) : E529 - E537
  • [5] Progression of hearing loss in neurofibromatosis type 2 according to genetic severity
    Emmanouil, Beatrice
    Houston, Rory
    May, Anne
    Ramsden, James D.
    Hanemann, C. Oliver
    Halliday, Dorothy
    Parry, Allyson
    Mackeith, Samuel
    LARYNGOSCOPE, 2019, 129 (04): : 974 - 980
  • [6] Efficacy of Cochlear Implantation in Neurofibromatosis Type 2 Related Hearing Loss
    Sobczak, Gabriel
    Marchant, Wendy
    Misurelli, Sara
    Pyle, Garrold Mark
    Gubbels, Samuel
    Roche, Joseph
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2023, 132 (03): : 284 - 293
  • [7] Neurofibromatosis type 1 causing conductive hearing loss
    Abbarah, Thabet
    Abbarah, M. Aiman
    ENT-EAR NOSE & THROAT JOURNAL, 2009, 88 (05) : 912 - 912
  • [8] Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2
    Shi-wei Li
    Jing Zhang
    Han-lu Tang
    Peng Li
    Bo Wang
    Fu Zhao
    Pi-nan Liu
    Journal of Neuro-Oncology, 2021, 155 : 373 - 381
  • [9] Surgical Management of Vestibular Schwannomas and Hearing Rehabilitation in Neurofibromatosis Type 2
    Tysome, James R.
    Macfarlane, Robert
    Durie-Gair, Juliette
    Donnelly, Neil
    Mannion, Richard
    Knight, Richard
    Harris, Frances
    Vanat, Zebunnisa H.
    Tam, Yu Chen
    Burton, Katherine
    Hensiek, Anke
    Raymond, F. Lucy
    Moffat, David A.
    Axon, Patrick R.
    OTOLOGY & NEUROTOLOGY, 2012, 33 (03) : 466 - 472
  • [10] Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2
    Li, Shi-Wei
    Zhang, Jing
    Tang, Han-Lu
    Li, Peng
    Wang, Bo
    Zhao, Fu
    Liu, Pi-Nan
    JOURNAL OF NEURO-ONCOLOGY, 2021, 155 (03) : 373 - 381